Another setback for Discovery Labs' Surfaxin in Phase II for ARF
This article was originally published in Scrip
Discovery Laboratories' troubled synthetic lung surfactant Surfaxin (lucinactant) has failed to show signs of efficacy in a Phase II study investigating it for decreasing the duration of mechanical ventilation in children with acute respiratory failure (ARF).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.